Evidence map›Paper›PMID 24825115›Full record

ArticleHepatology (Baltimore, Md.)2014

Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.

Mai T Pho, Benjamin P Linas

Abstract readEditorialComment
In one paragraph

Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Mai T PhoDepartment of Medicine, Sections of Hospital Medicine and of Infectious Diseases and Global Health, University of Chicago, Chicago, IL.
Benjamin P Linas

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment ProgramsR01DA027379 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHACKMAN, BRUCE R · 2009 to 2021
$5.3M
Simulation Modeling to Improve HIV/HCV Screening, Treatment and CareR01DA031059 · NIDA · BOSTON MEDICAL CENTER · PI LINAS, BENJAMIN P. · 2012 to 2015
$2.1M
Optimizing Patient-Oriented Outcomes for Chronic Hepatitis CK99HS022433 · AHRQ · UNIVERSITY OF CHICAGO · PI PHO, MAI TUYET · 2013 to 2014
$236k
AHRQ HHS 1K99HS022433-01AHRQ HHS K99 HS022433NCATS NIH HHS UL1 TR000430NIAID NIH HHS P30 AI042853NIDA NIH HHS R01 DA027379NIDA NIH HHS R01DA027379NIDA NIH HHS R01 DA031059NIDA NIH HHS R01DA031059
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis C, ChronicDrug CostsHepacivirusHeterocyclic Compounds, 3-RingHumansRibavirinSimeprevirSofosbuvirSulfonamidesUridine MonophosphateHeterocyclic Compounds, 3-RingRibavirinSimeprevirSofosbuvirSulfonamidesUridine Monophosphate

Identifiers

PMID24825115
PMCPMC4096113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.